<DOC>
<DOCNO>EP-0615440</DOCNO> 
<TEXT>
<INVENTION-TITLE>
MEDICAMENT CONTAINING A 2-ARYLPROPIONIC ACID DERIVATE AS A NANOSOL AND ITS PREPARATION
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31185	A61K910	A61K3119	A61K910	A61K951	A61K951	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61K	A61K	A61K	A61K	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61K9	A61K31	A61K9	A61K9	A61K9	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
ALFATEC PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
PAZ ARZNEIMITTELENTWICKLUNG
</APPLICANT-NAME>
<APPLICANT-NAME>
ALFATEC-PHARMA GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
PAZ ARZNEIMITTEL- ENTWICKLUNGSGESELLSCHAFT MBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
FREIDENREICH JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
LUKAS HELMUT
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHICK URSULA
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUSTER OTTO
</INVENTOR-NAME>
<INVENTOR-NAME>
WERRY JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
WUNDERLICH JENS-CHRISTIAN
</INVENTOR-NAME>
<INVENTOR-NAME>
FREIDENREICH, JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
LUKAS, HELMUT
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHICK, URSULA
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHUSTER, OTTO
</INVENTOR-NAME>
<INVENTOR-NAME>
WERRY, JUERGEN
</INVENTOR-NAME>
<INVENTOR-NAME>
WUNDERLICH, JENS-CHRISTIAN
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Immediate-effect medicament for the treatment of 
painful and/or inflammatory, and also febrile disorders, 

containing a pharmacologically active 2-arylpropionic 
acid derivative in the form of a pharmaceutically 

administrable nanosol which, as excipient, contains 
gelatin, a collagen hydrolysate or a gelatin derivative 

in addition to customary pharmaceutical auxiliaries. 
Medicament according to Claim 1, characterized in 
that the nanosol 


a) has an inner phase of the 2-arylpropionic acid 
derivative which has a particle size of 10-800 nm 

and possesses a surface charge, 
b) an outer phase of gelatin, a collagen hydrolysate or 
a gelatin derivative which is oppositely charged, 
c) a nearly or completely isoionic state charge of the 
inner and outer phase, and 
d) is physiologically absorbable. 
Medicament according to Claims 1 and/or 2, 
characterized in that the 2-arylpropionic acid derivative 

is present as a racemate or as a mixture at the racemate 
and its enantiomers. 
Medicament according to Claims 1 and/or 2, 
characterized in that the 2-arylpropionic acid derivative 

is present as a pseudoracemate. 
Medicament according to Claims 1 and/or 2,  
 

characterized in that the 2-arylpropionic acid derivative 
is present as a pure S-enantiomer or as a pure 

R-enantiomer. 
Medicament according to Claims 1 and/or 2, 
characterized in that the 2-arylpropionic acid derivative 

is present as a mixture of S- and R-enantiomers. 
Medicament according to one of Claims 1 to 6, 
characterized in that the 2-arylpropionic acid derivative 

is present as a liquid, aqueous nanodispersion. 
Medicament according to one of Claims 1 to 6, 
characterized in that the 2-arylpropionic acid derivative 

is present as a solid, resuspendable nanodispersion. 
Medicament according to one of Claims 1 to 8, 
characterized in that the 2-arylpropionic acid derivative 

has an average particle size of below 400 nm. 
Medicament according to one of Claims 1 to 9, 
characterized by an outer phase of the nanosol which 

additionally contains polyvinylpyrrolidone in a weight 
ratio of gelatin to polyvinylpyrrolidone such as 5:1 to 

500:1, preferably 10:1 to 50:1. 
Medicament according to one of Claims 1 to 10, 
characterized in that the 2-azylpropionic acid derivative 

is ketoprofen. 
Medicament according to one of Claims 1 to 10, 
characterized in that the 2-arylpropionic acid derivative 

is S-naproxen. 
Process for the preparation of a colloidally 
disperse system of a 2-arylpropionic acid derivative, 

characterized in that 

a) a gelatin, a collagen hydrolysate or a gelatin 
derivative is selected according to its isoelectric  

 
point (IEP) such that its IEP in coordinated with 

the charge state of the 2-arylpropionic acid derivative 
particles, leading the gelatin, the collagen 

hydrolysate or its derivative to charge neutrality 
with the undissolved 2-arylpropionic acid derivative 

at a specific pH, 
b) the gelatin, the collagen hydrolysate or its 
derivative is converted into the aqueous sol form, 
c) the pH is adjusted as a function of the IEP of the 
gelatin to a value such that the nanoparticles of 

the 2-arylpropionic acid derivative formed are 
nearly or completely stabilized in neutrally charged 

form, and 
d) before or after stage c) the 2-aryl-propionic acid 
derivative is dissolved in the aqueous gelatin sol 

or a solution of the 2-arylpropionic acid derivative 
is combined with the aqueous gelatin sol. 
Process according to Claim 13, characterized in 
that in stage d) the dissolved 2-arylpropionic acid 

derivative is converted into a colloidally disperse form 
of nanoparticles briefly before combination with the 

aqueous gelatin sol and the dispersion of nanoparticles 

thus obtained is continuously combined with the aqueous 
gelatin sol. 
Process according to Claim 13 or 14, 
characterized in that e1) the 2-arylpropionic acid 

derivative precipitates in the form of nanoparticles. 
Process according to Claim 13 or 14, 
characterized in that e2) the colloidally disperse 

solution obtained in stage d) is spray-dried or freeze-dried 
and thus a stable resuspendable nanosol is obtained 

which after redissolution in aqueous medium yields a 
colloidally disperse system in nanosol form. 
Process according to Claims 13 to 16, 
characterized in that in stage d) the 2-arylpropionic  

 
acid derivative is added dissolved in a water-miscible 

organic solvent. 
Process according to one of Claims 13 to 17, 
characterized in that the 2-arylpropionic acid derivative 

is converted into its salt. 
Process according to one of Claims 13 to 17, 
characterized in that the water-miscible organic solvent 

in stage b) is added to the aqueous gelatin sol and 
in stage d) the 2-arylpropionic acid derivative is added 

to this mixture in solid form and thus dissolved. 
Process according to Claim 17 or 19, 
characterized in that the organic solvent is then removed 

again. 
Process according to one of Claims 13 to 15, 
characterized in that the nanoparticle solution is then 

dried. 
Process according to Claim 21, characterized in 
that the solution is spray-dried. 
Process according to Claim 21, characterized in 
that the solution is freeze-dried. 
Process according to Claim 14 or 15, 
characterized in that, before adjustment of the pH to the 

isoionic point in stage c), the pH is adjusted such that 
the 2-arylpropionic acid derivative forms a salt. 
Process according to one of Claims 13 or 14, 
characterized in that following stage d) a water-miscible 

organic solvent is added to loosen the hydration shell of 
the gelatin molecules. 
Process according to Claim 25, characterized in 
that an alcohol in added.  

 
Process according to Claim 14, characterized in 
that the colloidal particles are produced continuously 

with an adjustable particle size. 
Process according to Claim 27, characterized in 
that the particle size is continuously measured. 
Process according to one of Claims 13 to 28, 
characterized in that it is carried out continuously. 
Process according to one of Claims 17 to 29, 
characterized in that in stage b) polyvinylpyrrolidone is 

additionally added in a ratio to the gelatin of 1 : 5 to 
1 : 500, preferably 1 : 10 to 1 : 50. 
Process according to one of Claims 1 to 30, 
characterized in that the gelatin employed is a gelatin 

having a maximum in the molecular weight distribution in 
the range 10⁴ - 10⁷ D. 
Process according to one of Claims 1 to 30, 
characterized in that the gelatin employed is a gelatin 

having a maximum in the molecular weight distribution of 
less than 10⁵ D (medium- to low-bloom). 
Process according to Claim 32, characterized in 
that a gelatin having a molecular weight distribution of 

10⁴ - 9.5 x 10⁴ D is employed. 
Process according to one of claims 1 to 32, 
characterized in that the solution rate of the eternal 

phase is increased by freeze- or spray-drying. 
Process according to one of Claims 13 to 30 and 
33, characterized in that a gelatin of 0 - 50 bloom is 

employed for the formation of tablets. 
Process according to one of Claims 13-35, 
characterized in that the 2-arylpropionic acid derivative  

 
is employed as a racemate. 
Process according to one of Claims 13-35, 
characterized in that the 2-arylpropionic acid derivative 

is employed as a racemate mixed with its enantiomers. 
Process according to one of Claims 13-35, 
characterized in that the 2-arylpropionic acid derivative 

is employed as a pseudoracemate. 
Process according to one of Claims 13-35, 
characterized in that the 2-arylpropionic acid derivative 

is employed as a pure S-enantiomer or pure R-enantiomer. 
Process according to one of Claims 13-35, 
characterized in that the 2-arylpropionic acid derivative 

is employed as a mixture of S- and R-enantiomers. 
</CLAIMS>
</TEXT>
</DOC>
